Package | hl7.fhir.uv.ebm |
Type | ImplementationGuide |
Id | Id |
FHIR Version | R6 |
Source | http://hl7.org/fhir/uv/ebm/https://build.fhir.org/ig/HL7/ebm/index.html |
Url | http://hl7.org/fhir/uv/ebm/ImplementationGuide/hl7.fhir.uv.ebm |
Version | 1.0.0-ballot2 |
Status | draft |
Date | 2025-05-20T09:03:07+00:00 |
Name | EBMIG |
Title | Evidence Based Medicine on FHIR Implementation Guide |
Experimental | False |
Realm | uv |
Authority | hl7 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: ImplementationGuide hl7.fhir.uv.ebm
The official URL for this implementation guide is:
http://hl7.org/fhir/uv/ebm/ImplementationGuide/hl7.fhir.uv.ebm
{
"resourceType" : "ImplementationGuide",
"id" : "hl7.fhir.uv.ebm",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: ImplementationGuide hl7.fhir.uv.ebm</b></p><a name=\"hl7.fhir.uv.ebm\"> </a><a name=\"hchl7.fhir.uv.ebm\"> </a><a name=\"hl7.fhir.uv.ebm-en-US\"> </a><h2>EBMIG</h2><p>The official URL for this implementation guide is: </p><pre>http://hl7.org/fhir/uv/ebm/ImplementationGuide/hl7.fhir.uv.ebm</pre></div>"
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode" : "cds"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status",
"valueCode" : "draft"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm",
"valueInteger" : 1
}
],
"url" : "http://hl7.org/fhir/uv/ebm/ImplementationGuide/hl7.fhir.uv.ebm",
"identifier" : [
{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.4.642.40.44"
}
],
"version" : "1.0.0-ballot2",
"name" : "EBMIG",
"title" : "Evidence Based Medicine on FHIR Implementation Guide",
"status" : "draft",
"date" : "2025-05-20T09:03:07+00:00",
"publisher" : "HL7 International / Clinical Decision Support",
"contact" : [
{
"name" : "HL7 International / Clinical Decision Support",
"telecom" : [
{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"jurisdiction" : [
{
"coding" : [
{
"system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code" : "001",
"display" : "World"
}
]
}
],
"packageId" : "hl7.fhir.uv.ebm",
"license" : "CC0-1.0",
"fhirVersion" : [
"6.0.0-ballot3"
],
"dependsOn" : [
{
"id" : "hl7_fhir_r6_core",
"uri" : "http://hl7.org/fhir/ImplementationGuide/fhir",
"packageId" : "hl7.fhir.r6.core",
"version" : "6.0.0-ballot3"
},
{
"id" : "hl7_fhir_uv_extensions",
"uri" : "http://hl7.org/fhir/extensions/ImplementationGuide/hl7.fhir.uv.extensions",
"packageId" : "hl7.fhir.uv.extensions",
"version" : "5.2.0"
},
{
"id" : "hl7_terminology",
"uri" : "http://terminology.hl7.org/ImplementationGuide/hl7.terminology",
"packageId" : "hl7.terminology",
"version" : "6.3.0"
}
],
"definition" : {
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/ig-internal-dependency",
"valueCode" : "hl7.fhir.uv.tools.r5#0.5.0"
}
],
"resource" : [
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267246"
},
"name" : "11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/55"
},
"name" : "14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)",
"description" : "COVID-19 pneumonia remdesivir vs. placebo 14-day mortality (779 events among 6,744 participants, 3 randomized trials)\nRisk ratio 0.85 (95% CI 0.74 to 0.96) in fixed-effect analysis\nRisk ratio 0.81 (95% CI 0.60 to 1.08) in random-effects analysis",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179628"
},
"name" : "14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267247"
},
"name" : "15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267496"
},
"name" : "15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "DeviceDefinition"
}
],
"reference" : {
"reference" : "DeviceDefinition/179899"
},
"name" : "179899",
"description" : "This is an example describing the Boots Finger Pulse Oximeter for use in an example of Group.characteristic.determinedByReference and does not contain substantial detail as the focus is not the expression of device definition details.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179602"
},
"name" : "18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179637"
},
"name" : "18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179631"
},
"name" : "19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179627"
},
"name" : "19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179603"
},
"name" : "19967827 Wonder woman was Argentine and her real name was Evita.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179626"
},
"name" : "22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179625"
},
"name" : "22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179615"
},
"name" : "23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179623"
},
"name" : "23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267501"
},
"name" : "23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179629"
},
"name" : "23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179624"
},
"name" : "24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179617"
},
"name" : "25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the \"Docetaxel Era\": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179622"
},
"name" : "26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179621"
},
"name" : "26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179630"
},
"name" : "26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179616"
},
"name" : "26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267500"
},
"name" : "26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267499"
},
"name" : "26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267498"
},
"name" : "26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/33089"
},
"name" : "27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179613"
},
"name" : "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/267497"
},
"name" : "27979893 6. Glycemic Targets.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179601"
},
"name" : "29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179600"
},
"name" : "29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179599"
},
"name" : "29202628 \"I Kinda Feel Like Wonder Woman\": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179598"
},
"name" : "29357271 Using Hawkeye from the Avengers to communicate on the eye.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179597"
},
"name" : "29694275 A regressive formula of perversity: Wertham and the women of comics.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179596"
},
"name" : "29694302 Introduction: \"Suffering Sappho!\": Lesbian content and queer female characters in comics.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179595"
},
"name" : "30467172 Finding my inner Wonder Woman.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/306957"
},
"name" : "30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179594"
},
"name" : "34871555 What Can Wonder Woman Teach Radiologists?",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/33399"
},
"name" : "35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179605"
},
"name" : "36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "DocumentReference"
}
],
"reference" : {
"reference" : "DocumentReference/367832"
},
"name" : "367832",
"description" : "Example of ResearchStudySupport Profile",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-support"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "DocumentReference"
}
],
"reference" : {
"reference" : "DocumentReference/367833"
},
"name" : "367833",
"description" : "Example of ResearchStudySupport Profile",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/research-study-support"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/264329"
},
"name" : "37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/179604"
},
"name" : "6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ResearchStudy"
}
],
"reference" : {
"reference" : "ResearchStudy/267245"
},
"name" : "A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example",
"description" : "This ResearchStudy Resource was derived from data in the ClinicalTrials.gov record then modified for use to support an M11 Report.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/m11-research-study"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/adaptation"
},
"name" : "Adaptation",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The Adaptation Profile is used for assessments of a knowledge artifact that are used to create a new knowledge artifact through acceptance, rejection or modification of the assessed artifact.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179683"
},
"name" : "ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version",
"description" : "An example of an EndpointAnalysisPlan Profile which uses intended='true' and include-if extensions within Evidence.statistic.modelCharacteristic elements.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/endpoint-analysis-plan"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/additional-language"
},
"name" : "AdditionalLanguage",
"description" : "The Resource contains content in a language additional to the one in the language element.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/265093"
},
"name" : "Adults with diabetes mellitus type 2",
"description" : "An example of CohortDefinition used to support a SystematicReviewEligibilityCriteria example.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/cohort-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/236533"
},
"name" : "Adults with diabetes type 2 and established CVD (but no CKD)",
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/236947"
},
"name" : "Adults with type 2 diabetes, CVD and CKD",
"description" : "This Group Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/297518"
},
"name" : "Age",
"description" : "Example of a VariableDefinition for the EBMonFHIR IG",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/298037"
},
"name" : "Age with comparator",
"description" : "Median Age 38.6 years (Standard Deviation 11.0 years)",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/298035"
},
"name" : "Age with intervention",
"description" : "Median Age 38.1 Years (Standard Deviation 8.7 years)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/297738"
},
"name" : "Aircraft Type",
"description" : "This EvidenceVariable Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/307431"
},
"name" : "Aircraft Type with comparator",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/307430"
},
"name" : "Aircraft Type with intervention",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "EvidenceVariable"
}
],
"reference" : {
"reference" : "EvidenceVariable/297740"
},
"name" : "Altitude",
"description" : "Example Variable Definition for EBMonFHIR IG",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/307447"
},
"name" : "Altitude comparing intervention vs. comparator",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/307444"
},
"name" : "Altitude for enrolled group",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/307442"
},
"name" : "Altitude for screened group",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/307251"
},
"name" : "Altitude with comparator",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/307250"
},
"name" : "Altitude with intervention",
"description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/306658"
},
"name" : "Analyzed Group in PARACHUTE Trial",
"description" : "Example of Analyzed Group Resource",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/study-group"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/7636"
},
"name" : "Anticoagulation for COVID-19 Combined RCTs in NEJM",
"description" : "The peer-reviewed report for combination of 3 adaptive RCTs",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/artifact-assessment-compared"
},
"name" : "ArtifactAssessmentCompared",
"description" : "The artifact being compared to the referenced artifact.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/artifact-assessment-date-as-rating"
},
"name" : "ArtifactAssessmentDateAsRating",
"description" : "A date or dateTime value as the classifier or rating value.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/312203"
},
"name" : "Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)",
"description" : "This Composition Resource is an example of a baseline measure report for the EBMonFHIR IG",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-measure-report"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "List"
}
],
"reference" : {
"reference" : "List/307202"
},
"name" : "Baseline Measures List for PARACHUTE Trial",
"description" : "This is an example baseline measures list for the EBMonFHIR IG",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-variables-list"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/baseline-measure-evidence"
},
"name" : "BaselineMeasureEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The BaselineMeasureEvidence Profile is used for evidence with a measured variable (with the role of outcome for this Evidence) that is considered an independent variable with respect to the outcome of an exposure or intervention in a study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179451"
},
"name" : "BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group",
"description" : "Age in Medical Group (n = 956) mean 45.7 years, SD 13.5 years",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179452"
},
"name" : "BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group",
"description" : "Age in Surgical Group (n = 932) mean 41.2 years, SD 10.5 years",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179458"
},
"name" : "BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group",
"description" : "BMI in Medical Group (n = 956) mean 42.9 kg/m2, SD 5.7 kg/m2",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179457"
},
"name" : "BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group",
"description" : "BMI in Surgical Group (n = 932) mean 45.4 kg/m2, SD 6.2 kg/m2",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/baseline-measure-report"
},
"name" : "BaselineMeasureReport",
"description" : "Profile of Composition for Evidence Based Medicine IG. The BaselineMeasureReport Profile is used for an evidence report including the findings for any number of baseline measures in a research study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/baseline-variables-list"
},
"name" : "BaselineVariablesList",
"description" : "Profile of List for Evidence Based Medicine IG. The BaselineVariablesList Profile is used to provide a list of EvidenceVariable Resources which represent baseline measures.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "List"
}
],
"reference" : {
"reference" : "List/312201"
},
"name" : "BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)",
"description" : "This is an example baseline variables list for the EBMonFHIR IG",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/baseline-variables-list"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ResearchStudy"
}
],
"reference" : {
"reference" : "ResearchStudy/264321"
},
"name" : "Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials",
"description" : "**Objective** To compare the benefits and harms of drug treatments for adults with type 2 diabetes, adding non-steroidal mineralocorticoid receptor antagonists (including finerenone) and tirzepatide (a dual glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist) to previously existing treatment options.\n**Design** Systematic review and network meta-analysis.\n**Data sources** Ovid Medline, Embase, and Cochrane Central up to 14 October 2022.\n**Eligibility criteria for selecting studies** Eligible randomised controlled trials compared drugs of interest in adults with type 2 diabetes. Eligible trials had a follow-up of 24 weeks or longer. Trials systematically comparing combinations of more than one drug treatment class with no drug, subgroup analyses of randomised controlled trials, and non-English language studies were deemed ineligible. Certainty of evidence was assessed following the GRADE (grading of recommendations, assessment, development and evaluation) approach.\n**Results** The analysis identified 816 trials with 471 038 patients, together evaluating 13 different drug classes; all subsequent estimates refer to the comparison with standard treatments. Sodium glucose cotransporter-2 (SGLT-2) inhibitors (odds ratio 0.88, 95% confidence interval 0.83 to 0.94; high certainty) and GLP-1 receptor agonists (0.88, 0.82 to 0.93; high certainty) reduce all cause death; non-steroidal mineralocorticoid receptor antagonists, so far tested only with finerenone in patients with chronic kidney disease, probably reduce mortality (0.89, 0.79 to 1.00; moderate certainty); other drugs may not. The study confirmed the benefits of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular death, non-fatal myocardial infarction, admission to hospital for heart failure, and end stage kidney disease. Finerenone probably reduces admissions to hospital for heart failure and end stage kidney disease, and possibly cardiovascular death. Only GLP-1 receptor agonists reduce non-fatal stroke; SGLT-2 inhibitors are superior to other drugs in reducing end stage kidney disease. GLP-1 receptor agonists and probably SGLT-2 inhibitors and tirzepatide improve quality of life. Reported harms were largely specific to drug class (eg, genital infections with SGLT-2 inhibitors, severe gastrointestinal adverse events with tirzepatide and GLP-1 receptor agonists, hyperkalaemia leading to admission to hospital with finerenone). Tirzepatide probably results in the largest reduction in body weight (mean difference −8.57 kg; moderate certainty). Basal insulin (mean difference 2.15 kg; moderate certainty) and thiazolidinediones (mean difference 2.81 kg; moderate certainty) probably result in the largest increases in body weight. Absolute benefits of SGLT-2 inhibitors, GLP-1 receptor agonists, and finerenone vary in people with type 2 diabetes, depending on baseline risks for cardiovascular and kidney outcomes (https://matchit.magicevidence.org/230125dist-diabetes).\n**Conclusions** This network meta-analysis extends knowledge beyond confirming the substantial benefits with the use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing adverse cardiovascular and kidney outcomes and death by adding information on finerenone and tirzepatide. These findings highlight the need for continuous assessment of scientific progress to introduce cutting edge updates in clinical practice guidelines for people with type 2 diabetes.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/book-citation"
},
"name" : "BookCitation",
"description" : "Profile of Citation for Evidence Based Medicine IG. The BookCitation Profile is used for citations of a book.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/121719"
},
"name" : "BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century",
"description" : "An example to map the BookCitation Profile",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/book-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/book-part-citation"
},
"name" : "BookPartCitation",
"description" : "Profile of Citation for Evidence Based Medicine IG. The BookPartCitation Profile is used for citations of a part of a book.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/139859"
},
"name" : "BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/book-part-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/139860"
},
"name" : "BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation",
"description" : "An example to map the BookCitation Profile",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/book-part-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/179693"
},
"name" : "Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)",
"description" : "This example of a CertaintyOfEvidence Profile shows a recursive pattern of component elements with type/classifier paired values for different aspects of rating the certainty of evidence.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/certainty-of-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/certainty-of-evidence"
},
"name" : "CertaintyOfEvidence",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The CertaintyOfEvidence Profile is used for expression of the certainty (also called quality or confidence in the estimates) of an Evidence artifact.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/characteristic-timing"
},
"name" : "CharacteristicTiming",
"description" : "Timing in which the characteristic is determined or action is taken.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179690"
},
"name" : "CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version",
"description" : "An example of an EndpointAnalysisPlan Profile which uses intended='true' and include-if extensions within Evidence.statistic.modelCharacteristic elements.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/endpoint-analysis-plan"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/247416"
},
"name" : "Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)",
"description" : "A citation of a Resource on the FEvIR Platform",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/database-entry-citation"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/58"
},
"name" : "Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)",
"description" : "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Citation"
}
],
"reference" : {
"reference" : "Citation/7638"
},
"name" : "Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19",
"description" : "A Evidence Resource to demonstrate complex evidence reporting",
"isExample" : true
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:extension"
}
],
"reference" : {
"reference" : "StructureDefinition/cite-as"
},
"name" : "CiteAs",
"description" : "Citation for this Resource.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/classification"
},
"name" : "Classification",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The Classification Profile is used for classifier tags that may be created independently from Resource creators and may be used for search indexes.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/179448"
},
"name" : "Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort",
"description" : "This Classification Profile example is used to represent the study design classifiers (as CodeableConcept datatype values) in support of a ComparativeEvidenceReport Profile.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/classification"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/cohort-definition"
},
"name" : "CohortDefinition",
"description" : "Profile of Group for Evidence Based Medicine IG. The CohortDefinition Profile is used to provide a definitional representation of a Group. The type element is required. (Alternatively, the ConceptualCohortDefinition Profile uses membership = conceptual and allows avoiding the required use of type.)",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comment"
},
"name" : "Comment",
"description" : "Profile of ArtifactAssessment for Evidence Based Medicine IG. The Comment Profile is used for comments about a Resource that may be created independently from Resource creators.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "ArtifactAssessment"
}
],
"reference" : {
"reference" : "ArtifactAssessment/179694"
},
"name" : "Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z",
"description" : "This example of a Comment Profile shows a comment about another Resource (Guideline Profile) in which the commenter is not the author of the Resource commented upon.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comment"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparative-baseline-measure-evidence"
},
"name" : "ComparativeBaselineMeasureEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The ComparativeBaselineMeasureEvidence Profile is used for comparative evidence with a measured variable (with the role of outcome for this Evidence) that is considered an independent variable with respect to the outcome of an exposure or intervention in a study.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179455"
},
"name" : "ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group",
"description" : "Mean age 41.2 in Surgical Group vs. 45.7 in Medical Group (p < 0.001)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/179456"
},
"name" : "ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group",
"description" : "Mean BMI 45.4 in Surgical Group vs. 42.9 in Medical Group (p < 0.001)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-baseline-measure-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparative-evidence"
},
"name" : "ComparativeEvidence",
"description" : "Profile of Evidence for Evidence Based Medicine IG. The ComparativeEvidence Profile is used for evidence with a measured variable that is considered the outcome of an exposure or intervention, and an exposure variable with two or more categories that are being compared.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/49328"
},
"name" : "ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis",
"description" : "effect estimate for bariatric surgery on all-cause mortality pooled hazard ratio (HR) 0.55 (95% confidence interval 0.49 to 0.62; P < 0.001 vs. controls) in meta-analysis of 21 cohort studies with 133,524 patients after bariatric surgery and 263,478 obese controls",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/32144"
},
"name" : "ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)",
"description" : "Of 120 participants who were initially randomized, 98 (82%) completed 5 years of follow-up. At 5 years, 13 participants (23%) in the gastric bypass group and 2 (4%) in the lifestyle-intensive medical management group had achieved the composite triple end point (difference, 19%; 95% CI, 4%-34%; P\t=\t.01).",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104157"
},
"name" : "ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study",
"description" : "Surgical patients had a greater risk for undergoing at least 1 additional gastrointestinal surgical procedure (AR, 31.3% vs 15.5%; RD, 15.8% [95% CI, 13.1%-18.5%]; RR, 2.0 [95% CI, 1.7-2.4]).",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104098"
},
"name" : "ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study",
"description" : "Bariatric surgery was associated with a reduced number of cardiovascular deaths (28 events among 2010 patients in the surgery group vs 49 events among 2037 patients in the control group; adjusted hazard ratio [HR], 0.47; 95% CI, 0.29-0.76; P = .002). The number of total first time (fatal or nonfatal) cardiovascular events (myocardial infarction or stroke, whichever came first) was lower in the surgery group (199 events among 2010 patients) than in the control group (234 events among 2037 patients; adjusted HR, 0.67; 95% CI, 0.54-0.83; P < .001). -- Extrapolated from this data the outcome of Nonfatal myocardial infarction or stroke occurred in 188 out of 2037 patients in the control group and 171 out of 2010 patients in the surgery group, and the adjusted HR for total events is assumed to apply (adjusted HR 0.67, 95% CI 0.54 to 0.83)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104155"
},
"name" : "ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study",
"description" : "greater risk of new-onset depression: AR, 8.9% vs 6.5%; RD, 2.4% [95% CI, 1.3%-3.5%], RR, 1.5 [95% CI, 1.4-1.7]",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104121"
},
"name" : "ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study",
"description" : "greater likelihood of diabetes remission: AR, 57.5% vs 14.8%; RD, 42.7% [95% CI, 35.8%-49.7%], RR, 3.9 [95% CI, 2.8-5.4]",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/104156"
},
"name" : "ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study",
"description" : "greater risk of treatment with opioids: AR, 19.4% vs 15.8%, RD, 3.6% [95% CI, 2.3%-4.9%], RR, 1.3 [95% CI, 1.2-1.4]",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47740"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014",
"description" : "Mean HbA1c at 12 months in Courcoulas 2014 was 6.6 % in Surgery group (n = 41) and 7.0% in Medical/Lifestyle group (n = 17), mean difference -0.40% (95% CI -0.89% to 0.09%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47768"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015",
"description" : "Mean HbA1c at 36 months in Courcoulas 2015 was 7.1% in Surgery group (n = 38) and 7.2% in Medical/Lifestyle group (n = 14), mean difference -0.10% (95% CI -0.35% to 0.15%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47759"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016",
"description" : "Mean HbA1c at 12 months in Cummings 2016 was 6.4% in Surgery group (n = 15) and 6.9% in Medical/Lifestyle group (n = 17), mean difference -0.50% (95% CI -1.52% to 0.52%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47748"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015",
"description" : "Mean HbA1c at 12 months in Ding 2015 was 7.17 % in Surgery group (n = 18) and 7.15% in Medical/Lifestyle group (n = 22), mean difference 0.02% (95% CI -0.16% to 0.20%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47760"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008",
"description" : "Mean HbA1c at 24 months in Dixon 2008 was 6% in Surgery group (n = 30) and 7.2% in Medical/Lifestyle group (n = 30), mean difference -1.20% (95% CI -1.78% to -0.62%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47749"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014",
"description" : "Mean HbA1c at 12 months in Halperin 2014 was 6.2 % in Surgery group (n = 19) and 8.8% in Medical/Lifestyle group (n = 19), mean difference -2.60% (95% CI -3.37% to -1.83%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47751"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013",
"description" : "Mean HbA1c at 12 months in Ikramuddin 2013 was 6.3 % in Surgery group (n = 57) and 7.8% in Medical/Lifestyle group (n = 19), mean difference -1.50% (95% CI -1.95% to -1.05%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47762"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015",
"description" : "Mean HbA1c at 24 months in Ikramuddin 2015 was 6.5% in Surgery group (n = 56) and 8.4% in Medical/Lifestyle group (n = 54), mean difference -1.90% (95% CI -2.78% to -1.02%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47752"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013",
"description" : "Mean HbA1c at 12 months in Liang 2013 was 6 % in Surgery group (n = 31) and 7.6% in Medical/Lifestyle group (n = 70), mean difference -1.60% (95% CI -1.94% to -1.26%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47665"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial",
"description" : "Mean HbA1c at 24 months in Mingrone 2012 was 5.65% in Surgery group (n = 20) and 7.69% in Medical/Lifestyle group (n = 20), mean difference -2.04% (95% CI -2.53% to -1.55%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47695"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial",
"description" : "Mean HbA1c at 60 months in Mingrone 2015 was 6.55% in Surgery group (n = 38) and 6.9% in Medical/Lifestyle group (n = 15), mean difference -0.35% (95% CI -0.69% to -0.01%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47738"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014",
"description" : "Mean HbA1c at 6 months in Parikh 2014 was 6.2 % in Surgery group (n = 20) and 7.8% in Medical/Lifestyle group (n = 24), mean difference -1.60% (95% CI -2.39% to -0.81%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47758"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial",
"description" : "Mean HbA1c at 12 months in Schauer 2012 was 6.5% in Surgery group (n = 99) and 7.5% in Medical/Lifestyle group (n = 41), mean difference -1.00% (95% CI -1.58% to -0.42%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47771"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial",
"description" : "Mean HbA1c at 36 months in Schauer 2014 was 6.85% in Surgery group (n = 97) and 8.4% in Medical/Lifestyle group (n = 40), mean difference -1.55% (95% CI -2.28% to -0.82%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/47766"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014",
"description" : "Mean HbA1c at 24 months in Wentworth 2014 was 6.1% in Surgery group (n = 23) and 7.3% in Medical/Lifestyle group (n = 25), mean difference -1.20% (95% CI -1.84% to -0.56%)",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Evidence"
}
],
"reference" : {
"reference" : "Evidence/33244"
},
"name" : "ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis",
"description" : "effect estimate for differences in mean HbA1c at study end point between Surgery and Medical/Lifestyle groups -1.14% (95% CI -1.57% to -0.71%) in meta-analysis of 15 trials with 1,067 participants",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparative-evidence-report"
},
"name" : "ComparativeEvidenceReport",
"description" : "Profile of Composition for Evidence Based Medicine IG. The ComparativeEvidenceReport Profile is used for an evidence report including the study group, exposure, comparator, and findings for any number of outcomes comparing the exposure to the comparator in the study group.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/178426"
},
"name" : "ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)",
"description" : "This example of a ComparativeEvidenceReport Profile shows a report from a single observational study with 2 baseline measures, 2 participant flow measures, and 4 outcome measures.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence-report"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparative-evidence-report-subject"
},
"name" : "ComparativeEvidenceReportSubject",
"description" : "Profile of Group for Evidence Based Medicine IG. The ComparativeEvidenceReportSubject Profile is used to define the subject of a ComparativeEvidenceReport.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Group"
}
],
"reference" : {
"reference" : "Group/179633"
},
"name" : "ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)",
"description" : "This example of a ComparativeEvidenceReportSubject Profile expresses the conceptual group of PICO elements using the 'all of'' code in the combinationMethod element. Each of the characteristics described in this example are defined by reference to another Resource so the characteristic.code element has a value of text:'Defined by Reference' and uses a valueReference element. Three of the characteristics are defined by reference to a Group Resource and the last characteristic (Outcomes) is defined by reference to a List Resource. This example demonstrates the use of the 'conceptual' code for the membership element. In this case the Group Resource is being used for the conceptual grouping of characteristics and is not a group of people or physical objects.",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence-report-subject"
]
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "StructureDefinition:resource"
}
],
"reference" : {
"reference" : "StructureDefinition/comparative-evidence-synthesis-report"
},
"name" : "ComparativeEvidenceSynthesisReport",
"description" : "Profile of Composition for Evidence Based Medicine IG. The ComparativeEvidenceSynthesisReport Profile is used for an evidence report including the intended population, intended exposure, intended comparator, and findings for any number of outcomes comparing the exposure to the comparator with observed study group, observed exposure group, and observed comparator group unique for each outcome.",
"isExample" : false
},
{
"extension" : [
{
"url" : "http://hl7.org/fhir/tools/StructureDefinition/resource-information",
"valueString" : "Composition"
}
],
"reference" : {
"reference" : "Composition/236538"
},
"name" : "ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk",
"description" : "Example of ComparativeEvidenceSynthesisReport Profile",
"isExample" : true,
"profile" : [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence-synthesis-report"
]
},
{
"extension" : [
{
&